Q2 FY2026 EarningsQ2 FY26 results significantly beat analyst expectations on the bottom line, with a GAAP net loss of -$6.5M vs. the -$16.3M consensus, and GAAP EPS of -$2.62 vs. the -$3.77 consensus mean. Revenue of $1.92M missed the $3.11M consensus due to lower reimbursable research activities. However, the completion of a $155.5M upsized IPO and private placement in July 2026 extends the company's cash runway into H1 2029, providing significant financial stability for its clinical-stage CRISPR pipeline.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Scribe Therapeutics(SCTX) the Revenue is 1.918 M (--%), Miss estimate;the EBIT is -9.395 M (--%), Beat estimate;the EPS is -2.62 (--%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B--
0.00B--
-0.00B--%
EBITExceed expectations
-0.01B--
-0.02B--
+0.01B--%
EPSExceed expectations
-2.62--
-3.7725--
+1.1525--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf